Speaker
Description
Emerging trends in nuclear medicine are expanding the development of novel radiotracers within the light nuclei range driven by advancements in imaging technologies [1]. This evolution demands the optimization of production routes for clinically significant isotopes. To address this, the present study investigates key production reactions utilizing the EMPIRE-3.2 code. By employing the Hauser-Feshbach formalism and the Exciton model, we predict reaction cross-sections in the 2–30~MeV energy range to evaluate theoretical feasibility [2]. This theoretical investigation targets the optimization of production routes for the widely used non-metallic positron emitters $^{11}\text{C}$, $^{13}\text{N}$, $^{15}\text{O}$, and $^{18}\text{F}$.
Calculated cross-sections are validated against experimental data from the EXFOR library and evaluations from TENDL [3] to ensure compatibility with low-to-moderate energy, in-house medical cyclotrons. To evaluate the dosimetry profiles of these tracers, this work utilizes GEANT4 simulations [5] to calculate internal absorbed doses and S-values within the ICRP 145 mesh-based reference computational phantom (MRCP) [4]. Furthermore, to demonstrate the broader radiation protection utility of this phantom setup, we evaluate external effective dose coefficients (dose-per-fluence) across 10 distinct incident radiation fields, extending from indirectly ionizing radiation (photons and neutrons) to charged particles (protons, electrons, and muons etc.).
To complement the cross-section evaluations, organ-specific S-values are calculated for nine source organs for each radiotracer, culminating in the generation of 3D dose distribution maps. To address the fact that current theoretical predictions deviate from scattered and historically inconsistent experimental data [6], this work emphasize on the evaluation of the $^{14}\text{N}(\text{p},\alpha)^{11}\text{C}$ reaction via the irradiation of an Aluminium Nitride (AlN) solid target to analyze the $^{11}\text{C}$ production yield. AlN was selected for its high nitrogen density and exceptional thermal stability, providing a strategic pathway to improve the production yield of $^{11}\text{C}$ for clinical facilities.
[1] M. Singh, D. P. Singh, and K. Pandey, in Environmental and Health Studies, vol. 0, no. 0, pp. 1–57, (2025)
[2] M. Herman et al.,Nuclear Data Sheets, vol. 108, no. 12, pp. 2655–2715, (2007)
[3] M. Singh, K. Kholiya, D. P. Singh, and K. Pandey, Journal of Taibah University for Science, vol. 19, no. 1, p. 2572147, (2025)
[4] C. H. Kim et al., Ann ICRP, vol. 49, no. 3, pp. 13–201, Oct. 2020
[5] S. Agostinelli et al., Nuclear Instruments and Methods in Physics Research Section A, vol. 506, no. 3, pp. 250–303, (2003)
[6] Nuclear Data Section: https://www-nds.iaea.org/
Comments to the Scientific Committee
If possible, I would like to request financial support for the conference registration and travel.
Thanks
| Keywords | Nuclear Medicine, EMPIRE-3.2, ICRP 145 Phantom, GEANT4, S-values, 11C production |
|---|---|
| Proceedings Publication Intent | Yes |
| Student Award Eligibility | yes |
| Financial Support Request | yes |